(ReprintedAssembly withBill amendmentsNo. adopted on May 19, 2025) FIRST REPRINT A.B.

411411–Assemblymember ASSEMBLYJauregui BILLCHAPTER.......... NO .

411–ASSEMBLYMEMBER JAUREGUI M ARCH 12, 2025 ____________ Referred to Committee on Health and Human Services SUMMARY—Revises provisions relating to prescription drugs.

(BDR 54-1100) FISCAL NOTE:

Effect on Local Government:

No.

Effect on the State:

No.

~ EXPLANATION – Matter in bolded italics is new;

matter between brackets [omitted material] is material to be omitted.

EXPLANATION – Matter in bolded italics is new;

matter between brackets [omitted material] is material to be omitted.

[The] Except as otherwise provided in this subsection, the names of the prescribing practitioner and of the person for whom prescribed.affixed label or device for a prescription for mifepristone,an misoprostol or their generic alternatives may include the name of the prescribing health care practice instead of the name of the prescribing practitioner.

Upon4. request from the prescribing practitioner, an - *AB411_R1* – 2 – affixed label or device for a prescription for mifepristone, misoprostol or their generic alternatives may include the name of the prescribing health care practice instead of the name of the prescribing practitioner.

The number of dosage units.

If the expiration date specified by the manufacturer is not less than 1 year after the - 83rd Session (2025) – 2 – date of dispensing, the practitioner may use a date that is 1 year after the date of dispensing as the expiration date.

H~~~~~ 25 - *AB411_R1*83rd Session (2025)